Activation of Poly(ADP-Ribose) Polymerase by Myocardial Ischemia and Coronary Reperfusion in Human Circulating Leukocytes
暂无分享,去创建一个
I. Préda | K. Murthy | C. Szabó | R. Kiss | E. Pankotai | E. Horváth | Z. Lacza | T. Bárány | K. Vargová | Domokos Gerö | Z. Zsengellér | K. Fekete | T. Pék | E. Tóth-Zsámboki
[1] C. Szabó. Cardioprotective effects of poly(ADP-ribose) polymerase inhibition. , 2005, Pharmacological research.
[2] G. Graziani,et al. Clinical perspectives of PARP inhibitors. , 2005, Pharmacological research.
[3] Csaba Szabó,et al. Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors , 2005, Nature Reviews Drug Discovery.
[4] M. Fuertes,et al. Poly(ADP-ribose) polymerases: homology, structural domains and functions. Novel therapeutical applications. , 2005, Progress in biophysics and molecular biology.
[5] C. Vrints,et al. Myocardial ischemia/reperfusion-injury, a clinical view on a complex pathophysiological process. , 2005, International journal of cardiology.
[6] C. Szabó,et al. Mitochondrial-to-nuclear translocation of apoptosis-inducing factor in cardiac myocytes during oxidant stress: potential role of poly(ADP-ribose) polymerase-1. , 2004, Cardiovascular research.
[7] D. Giugliano,et al. Intermittent high glucose enhances ICAM‐1, VCAM‐1, E‐selectin and interleukin‐6 expression in human umbilical endothelial cells in culture: the role of poly(ADP‐ribose) polymerase , 2004, Journal of thrombosis and haemostasis : JTH.
[8] K. Murthy,et al. Activation of Poly(ADP-Ribose) Polymerase in Circulating Leukocytes During Myocardial Infarction , 2004, Shock.
[9] J. Yélamos,et al. Transcription regulation of TNF-alpha-early response genes by poly(ADP-ribose) polymerase-1 in murine heart endothelial cells. , 2004, Nucleic acids research.
[10] F. Sellke,et al. Poly(ADP-ribose) polymerase inhibition improves postischemic myocardial function after cardioplegia-cardiopulmonary bypass. , 2003, Journal of the American College of Surgeons.
[11] É. Szabó,et al. Peroxynitrite-induced cytotoxicity: mechanism and opportunities for intervention. , 2003, Toxicology letters.
[12] C. Schäfer,et al. Cellular mechanisms of ischemia-reperfusion injury. , 2003, The Annals of thoracic surgery.
[13] C. Szabó,et al. The Therapeutic Potential of Poly(ADP-Ribose) Polymerase Inhibitors , 2002, Pharmacological Reviews.
[14] M. Simoons,et al. Minor Myocardial Damage and Prognosis: Are Spontaneous and Percutaneous Coronary Intervention–Related Events Different? , 2002, Circulation.
[15] É. Szabó,et al. Suppression of poly (ADP‐ribose) polymerase activation by 3‐aminobenzamide in a rat model of myocardial infarction: long‐term morphological and functional consequences , 2001, British journal of pharmacology.
[16] Z. Berente,et al. Effect of poly(ADP-ribose) polymerase inhibitors on the ischemia-reperfusion-induced oxidative cell damage and mitochondrial metabolism in Langendorff heart perfusion system. , 2001, Molecular pharmacology.
[17] R. Califf,et al. The relationship between periprocedural myocardial infarction and subsequent target vessel revascularization following percutaneous coronary revascularization: insights from the EPIC trial. Evaluation of IIb/IIIa platelet receptor antagonist 7E3 in Preventing Ischemic Complications. , 1999, Journal of the American College of Cardiology.
[18] R. Ferrari,et al. Metabolic derangement in ischemic heart disease and its therapeutic control. , 1998, The American journal of cardiology.
[19] B. Zingarelli,et al. Genetic disruption of poly (ADP-ribose) synthetase inhibits the expression of P-selectin and intercellular adhesion molecule-1 in myocardial ischemia/reperfusion injury. , 1998, Circulation research.
[20] R. Califf,et al. Myonecrosis after revascularization procedures. , 1998, Journal of the American College of Cardiology.
[21] S. Cuzzocrea,et al. Protection against myocardial ischemia and reperfusion injury by 3-aminobenzamide, an inhibitor of poly (ADP-ribose) synthetase. , 1997, Cardiovascular research.
[22] B. Zingarelli,et al. Protection by inhibition of poly (ADP-ribose) synthetase against oxidant injury in cardiac myoblasts In vitro. , 1997, Journal of molecular and cellular cardiology.
[23] S. Maxwell,et al. Reperfusion injury: a review of the pathophysiology, clinical manifestations and therapeutic options. , 1997, International journal of cardiology.
[24] C. Thiemermann,et al. Inhibition of the activity of poly(ADP ribose) synthetase reduces ischemia-reperfusion injury in the heart and skeletal muscle. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[25] M. Brown,et al. A Randomised Controlled Trial of Vitamin E in Patients with Coronary Disease: The Cambridge Heart Antioxidant Study (CHAOS) , 1996 .
[26] F. Kelly,et al. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS) , 1996, The Lancet.
[27] D. Carrié,et al. Myocardial protection with calcium-channel blockers during ischaemia and reperfusion by PTCA. , 1995, European heart journal.
[28] J. Kirkland,et al. Lipid peroxidation, protein thiol oxidation and DNA damage in hydrogen peroxide-induced injury to endothelial cells: role of activation of poly(ADP-ribose)polymerase. , 1991, Biochimica et biophysica acta.
[29] J. Zweier. Measurement of superoxide-derived free radicals in the reperfused heart. Evidence for a free radical mechanism of reperfusion injury. , 1988, The Journal of biological chemistry.
[30] E. Braunwald,et al. Myocardial reperfusion: a double-edged sword? , 1985, The Journal of clinical investigation.
[31] M S Golden,et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. , 1980, The New England journal of medicine.
[32] H. Eltzschig,et al. Vascular ischaemia and reperfusion injury. , 2004, British medical bulletin.
[33] Z. Yang,et al. Effect of genetic disruption of poly (ADP-ribose) synthetase on delayed production of inflammatory mediators and delayed necrosis during myocardial ischemia-reperfusion injury. , 2000, Shock.